Comparative practicability and analytical performances of Credo VitaPCR™ Flu A&B and Cepheid Xpert® Xpress Flu/RSV platforms.
Diagn Microbiol Infect Dis
; 100(4): 115381, 2021 Aug.
Article
in English
| MEDLINE | ID: covidwho-1269260
ABSTRACT
To compare the practicability (usability and satisfaction) and analytical performances of VitaPCR™ Flu A&B Assay (Credo Diagnostics Biomedical Pte. Ltd., Singapore, Republic of Singapore) and Xpert® Xpress Flu/RSV kit (Cepheid, Sunnyvale, USA), two rapid point-of-care (POC) nucleic acid amplification tests (NAATs) by reference to multiplex RT-PCR for respiratory viruses. Nasopharyngeal swabs (n=117) were collected from patients with influenza-like illness in Paris, France. Thawed specimens were further analyzed with both NAATs. The usability was comparable for both NAATs. Satisfaction questionnaire was better for the VitaPCR™ platform for the short time of test result in 20 minutes. Both NAATs showed comparable sensitivities (VitaPCRTM 95.0%; Xpert® Xpress 97.5%) and specificities (100%) for influenza A/B RNA detection, with excellent reliability and accuracy between both NAATs. Both VitaPCR™ and Xpert® Xpress NAATs can be implemented in hospital setting as POC NAATs to rapidly detect influenza A/B RNA in symptomatic patients.
Keywords
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Reagent Kits, Diagnostic
/
Viruses
/
Molecular Diagnostic Techniques
/
Real-Time Polymerase Chain Reaction
Type of study:
Diagnostic study
/
Observational study
Limits:
Humans
Language:
English
Journal:
Diagn Microbiol Infect Dis
Year:
2021
Document Type:
Article
Affiliation country:
J.diagmicrobio.2021.115381
Similar
MEDLINE
...
LILACS
LIS